WCN26-2713 EFFECT OF TENAPANOR ON BODY FLUID VOLUME AND BLOOD PRESSURE IN PERITONEAL DIALYSIS PATIENTS: A PROSPECTIVE OBSERVATIONAL STUDY

Read full text Summarise with VIRAT
Authors: Shun Yoshida, Kengo Asahina, Keiichi Osano, K. Yamamura, Kie Ohkoshi, Miho Shikata, Toshihisa Ishii, Makiko Konishi, Kazuya Takahashi, Ayumu Nakashima
Cited by: 0

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Tenapanor is a novel phosphate-lowering agent that inhibits the intestinal sodium-hydrogen exchanger 3 (NHE3). Its theoretical mechanism of action suggests that it influences by reducing intestinal sodium absorption. However, there is limited clinical evidence on the hemodynamic effects of tenapanor. We evaluated the effects of tenapanor on fluid dynamics and blood pressure in patients undergoing peritoneal dialysis (PD).

Fields of Study & Subjects

Dialysis and Renal Disease Management Parathyroid Disorders and Treatments Ion Transport and Channel Regulation

Publication details

Journal / source
Kidney International Reports
Volume
11
Issue
4
Pages
105859–105859
Publication date
25 March 2026
Language
EN